Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response

Few pharmacologic options exist for patients with clozapine-resistant schizophrenia (CRS) or schizoaffective disorder. Xanomeline/trospium represents a new class of antipsychotic medication that has efficacy as monotherapy for schizophrenia. Despite distinct mechanistic differences from standard ant...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Vanessa M. Dang, John M. Powers, Matej Markota, Jonathan G. Leung
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SAGE Publishing 2026-03-01
Edice:	Therapeutic Advances in Psychopharmacology
On-line přístup:	https://doi.org/10.1177/20451253261433832
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!